R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AIGene therapy

HuidaGene Secures US Patent for High-Efficiency Cas12Max DNA Editing System

COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development

Generic drugsGQCE testing

China’s CDE Releases 69th Batch of Generic Chemical Reference Preparations for Public Review

CancerCAR-T

AACR 2023 Highlights: CAR-T Therapies and Monoclonal Antibody Combinations in Cancer Research

Show More